MedTrace Logo

A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00332215 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2008-12-01

No results posted yet for this study

Summary

The primary objective of this study is to assess the safety of inhaled sodium pyruvate in people with Cystic Fibrosis (CF). Further, to determine whether inhaled sodium pyruvate will improve lung function, as determined by FEV1, or reduce inflammatory markers in induced sputum of people with CF.

Conditions

Interventions

DRUG

Inhaled Sodium Pyruvate

Sponsors & Collaborators

Principal Investigators

  • Carlos E Milla, MD · University of Minnesota

  • Joanne L Billings, MD, MPH · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332215 on ClinicalTrials.gov